ArticleMembranes2018
Utilization of DES-Lignin as a Bio-Based Hydrophilicity Promoter in the Fabrication of Antioxidant Polyethersulfone Membranes.
Article in Membranes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- Effect of Low Concentrations of Lithium Chloride Additive on Cellulose-Rich Ultrafiltration Membrane Performance.Membranes · 2023Article
- Cellulose Nanofibers Derived Surface Coating in Enhancing the Dye Removal with Cellulosic Ultrafiltration Membrane.Membranes · 2022Article
- Cellulose Membranes in the Treatment of Spent Deep Eutectic Solvent Used in the Recovery of Lignin from Lignocellulosic Biomass.Membranes · 2022Article
- Comparative investigation of the structural characteristics of tobacco stalk lignin during the DES and alkaline deconstruction toward sustainable materials.Frontiers in bioengineering and biotechnology · 2022Article
- Review
- Review
- Vanillin as an Antifouling and Hydrophilicity Promoter Agent in Surface Modification of Polyethersulfone Membrane.Membranes · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Enhancement of membrane permeability at no detriment of its other performances, e.g., selectivity, is a goal-directed objective in membrane fabrication. A novel antioxidant DES-lignin (lignin extracted from birch wood by using a deep eutectic solvent) polyethersulfone (PES) membrane, containing 0⁻1 wt % DES-lignin, was fabricated with the phase inversion technique. The performance and morphology of the fabricated membranes were characterized by a pure water flux, polyethylene glycol (PEG) retention, Fourier transform infrared spectroscopy, scanning electron microscopy, and contact angle measurements. Membranes with less negative charge and better hydrophilicity were obtained when the DES-lignin content in the polymer solution was increased. With the highest dosage, the incorporation of DES-lignin in the membrane matrix improved the membrane permeability by 29.4% compared to a pure PES membrane. Moreover, no leakage of DES-lignin from the membrane structure was observed, indicating good compatibility of DES-lignin with the PES structure. It was also found that the improvement of both rejection and pure water flux could be achieved by using a small dosage of DES-lignin (0.25 wt %) in membrane fabrication. The membranes incorporated with DES-lignin showed higher DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS (2,2-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid)) scavenging activity compared to the pure membrane, where 2.6 and 1.1 times higher DPPH and ABTS scavenging activity was observed with the highest DES-lignin content (1 wt %). Thus, the results of this study demonstrate well the feasibility of utilizing DES-lignin as an antioxidant bio-based hydrophilicity promoter in the fabrication of ultrafiltration membranes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.